2012 North American Cystic Fibrosis Conference Kicks Off in Orlando, Fla.
October 11, 2012
Nearly 4,000 doctors, scientists and caregivers from around the world are gathering today in Orlando, Fla., for the 26th annual North American Cystic Fibrosis Conference (NACFC), sponsored by the Cystic Fibrosis Foundation.
The meeting takes place at a time of tremendous advances in cystic fibrosis research and care. In January, the U.S. Food and Drug Administration approved the first drug, Kalydeco™, to treat the underlying cause of CF in a small group of people with the disease, opening the door to research that may eventually lead to similar treatments for all those living with CF.
“We are at a pivotal moment in the history of cystic fibrosis," said Robert J. Beall, Ph.D., president and CEO of the CF Foundation. “The hope and optimism in the CF community today is thanks in large part to the talent and energy of people from around the world who are dedicated to improving the lives of those with CF and working together to speed our progress toward a cure.”
From Oct. 11 through Oct. 13, attendees will meet and exchange ideas on the latest in CF research, care and drug development. Highlights of the 2012 NACFC include:
- Accelerating discovery of potential new therapies that target the basic genetic defect in CF.
- Updates on the diagnosis and management of pulmonary disease.
- Overcoming barriers to CF medication adherence.
- Partnering with patients and families to improve CF care.
Get updates during NACFC by following us on Twitter.